Endometrial Carcinoma

  • Tricia A. Murdock
  • Emanuela F. T. Veras
  • Robert J. Kurman
  • Michael T. Mazur


Endometrial carcinoma is the 4th most common cancer for American women and the most common malignant tumor of the female genital tract. In the United States in 2015, there were 54,644 new cases and 10,096 deaths resulting from this neoplasm. Black women have a much higher rate of mortality when compared to white women. Although most endometrial carcinomas that are diagnosed at early stages have an excellent survival rate, this neoplasm represents a biologically and morphologically diverse group of tumors, with differing pathogenesis, behavior, and prognosis. These tumors were grouped into two types based on clinicopathologic features designated “Type I and Type II”. This grouping was helpful in understanding the pathogenesis of endometrial cancer, but it is important to understand that this is not a histopathologic classification. The prototypic Type I tumor is the usual type of endometrioid carcinoma, and the prototypic Type II tumor is serous carcinoma.


Endometrial carcinoma Malignant endometrial neoplasms FIGO grading of endometrial carcinoma Hereditary nonpolyposis colorectal cancer (Lynch syndrome) Cowden syndrome Endometrioid carcinoma variants Endometrial carcinoma mimics 


  1. 1.
    U.S. Cancer Statistics Working Group. United States cancer statistics: 2015 Incidence and mortality web-based report. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2017. Available at: Scholar
  2. 2.
    Farley J, Risinger JI, Rose GS, Maxwell GL. Racial disparities in blacks with gynecologic cancers. Cancer. 2007;110(2):234–43.PubMedGoogle Scholar
  3. 3.
    Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomark Prev. 2015;24(9):1407–15.Google Scholar
  4. 4.
    Smith M, McCartney AJ. Occult, high-risk endometrial cancer. Gynecol Oncol. 1985;22:154–61.PubMedGoogle Scholar
  5. 5.
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.PubMedGoogle Scholar
  6. 6.
    Ellenson LH, Ronnett BM, Soslow RA. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 6th ed. New York: Springer; 2011. p. 393–452.Google Scholar
  7. 7.
    Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91(13):1131–7.PubMedGoogle Scholar
  9. 9.
    Longacre TA, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am J Surg Pathol. 1999;23:69–78.PubMedGoogle Scholar
  10. 10.
    Landry D, Mai KT, Senterman MK, Perkins DG, Yazdi HM, Veinot JP, et al. Endometrioid adenocarcinoma of the uterus with a minimal deviation invasive pattern. Histopathology. 2003;42:77–82.PubMedGoogle Scholar
  11. 11.
    Soslow RA. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol. 2010;27(4):261–73.PubMedGoogle Scholar
  12. 12.
    Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2013;37(6):874–81.PubMedGoogle Scholar
  13. 13.
    Lomo L, Nucci MR, Lee KR, Lin MC, Hirsch MS, Crum CP, Mutter GL. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol. 2008;21(8):937–42.PubMedGoogle Scholar
  14. 14.
    Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, Ewanowich CA, Kalloger SE, Köbel M. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013;26(12):1594–604.PubMedGoogle Scholar
  15. 15.
    Thomas S, Hussein Y, Bandyopadhyay S, Cote M, Hassan O, Abdulfatah E, Alosh B, Guan H, Soslow RA, Ali-Fehmi R. Interobserver variability in the diagnosis of uterine high-grade endometrioid carcinoma. Arch Pathol Lab Med. 2016;140(8):836–43.PubMedPubMedCentralGoogle Scholar
  16. 16.
    DF DL, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, Mohanty AS, Cheng DT, Berger MF, Soslow RA, Weigelt B. The genetic landscape of endometrial clear cell carcinomas. J Pathol. 2017;243(2):230–41.Google Scholar
  17. 17.
    Bosse T, Nout RA, JN MA, MK MC, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol. 2018;42(5):561–8.PubMedGoogle Scholar
  18. 18.
    Goebel EA, Vidal A, Matias-Guiu X, Blake Gilks C. The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. Virchows Arch. 2017;472(6):885–96.PubMedGoogle Scholar
  19. 19.
    Stelloo E, Bosse T, Nout RA, HJ MK, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836–44.PubMedGoogle Scholar
  20. 20.
    Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802–13.PubMedGoogle Scholar
  21. 21.
    Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180–8.PubMedGoogle Scholar
  22. 22.
    Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Köbel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol Oncol. 2016;143(1):46–53.PubMedPubMedCentralGoogle Scholar
  23. 23.
    DiSaia PJ, Creasman WT. Clinical gynecologic oncology. 6th ed. St. Louis: Mosby-Year Book; 2002.Google Scholar
  24. 24.
    Hendrickson MR, Ross JC, Kempson RL. Toward the development of morphologic criteria for well-differentiated adenocarcinoma of the endometrium. Am J Surg Pathol. 1983;7:819–38.PubMedGoogle Scholar
  25. 25.
    Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49:2547–57.PubMedGoogle Scholar
  26. 26.
    Norris HJ, Tavassoli FA, Kurman RJ. Endometrial hyperplasia and carcinoma. Diagnostic considerations. Am J Surg Pathol. 1983;7:839–47.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Kraus FT. High-risk and premalignant lesions of the endometrium. Am J Surg Pathol. 1985;9(Suppl):31–40.Google Scholar
  28. 28.
    Ellenson LH, Ronnett BM, Kurman RJ. Precursor lesions of endometrial carcinoma. In: Kurman R, editor. Blaustein’s pathology of the female genital tract. 6th ed. New York: Springer; 2011. p. 359–91.Google Scholar
  29. 29.
    Lehman MB, Hart WR. Simple and complex hyperplastic papillary proliferations of the endometrium: a clinicopathologic study of nine cases of apparently localized papillary lesions with fibrovascular stromal cores and epithelial metaplasia. Am J Surg Pathol. 2001;25:1347–54.PubMedGoogle Scholar
  30. 30.
    King A, Seraj IM, Wagner RJ. Stromal invasion in endometrial carcinoma. Am J Obstet Gynecol. 1984;149:10–4.PubMedGoogle Scholar
  31. 31.
    Zaino R, Carinelli S, Ellenson L. Uterine corpus: epithelial tumours and precursors. In: Kurman R, Carcangiu M, Herrington C, Young R, editors. World health organization classification of tumours of the female reproductive organs. 4th ed. Lyon: IARC; 2014. p. 125–35.Google Scholar
  32. 32.
    Connelly PJ, Alberhasky RC, Christopherson WM. Carcinoma of the endometrium. III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol. 1982;59:569–75.PubMedGoogle Scholar
  33. 33.
    Hendrickson M, Ross J, Eifel PJ, Cox RJ, Martinez A, Kempson R. Adenocarcinoma of the endometrium: An analysis of 256 cases with carcinoma limited to the uterine corpus. I. Pathology review and analysis of prognostic variables. Gynecol Oncol. 1982;13:373–92.PubMedGoogle Scholar
  34. 34.
    Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: A review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2002;9:145–84.PubMedGoogle Scholar
  35. 35.
    Ferlay J, Shin HR, Bray F, Forman D, et al. Cancer incidence and mortality worldwide (2008): IARC CancerBase. IARC.Google Scholar
  36. 36.
    Zaino RJ, Kurman R, Herbold D, Gliedman J, Bundy BN, Voet R, et al. The significance of squamous differentiation in endometrial carcinoma—Data from a Gynecologic Oncology Group study. Cancer. 1991;68:2293–302.PubMedGoogle Scholar
  37. 37.
    Abeler VM, Kjorstad KE. Endometrial adenocarcinoma with squamous cell differentiation. Cancer. 1992;69:488–95.PubMedGoogle Scholar
  38. 38.
    Demopoulos RI, Dubin N, Noumoff J, et al. Prognostic significance of squamous differentiation in stage I endometrial adenocarcinoma. Obstet Gynecol. 1986;68:245–50.PubMedGoogle Scholar
  39. 39.
    Zaino RJ, Kurman RJ, Diana KL, Morrow CP. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer. 1995;75:81–6.PubMedGoogle Scholar
  40. 40.
    Nordstrom B, Strang P, Lindgren A, Bergstrom R, Tribukait B. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res. 1996;16:899–904.PubMedGoogle Scholar
  41. 41.
    Ayhan A, Taskiran C, Yuce K, Kucukali T. The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma. Int J Gynecol Pathol. 2003;22:71–4.PubMedGoogle Scholar
  42. 42.
    Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks B. Assessment of a novel grading system for endometrial carcinoma. Mod Pathol. 2003;16:180A.Google Scholar
  43. 43.
    Benedet JL, Bender H, Jones H, III NHY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–62.PubMedGoogle Scholar
  44. 44.
    Christopherson WM, Connelly PJ, Alberhasky RC. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer. 1983;51:1705–9.PubMedGoogle Scholar
  45. 45.
    Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: II. Papillary adenocarcinoma: a clinical pathologic study of 46 cases. Am J Clin Pathol. 1982;77:534–40.PubMedGoogle Scholar
  46. 46.
    Daniel AG, Peters WA III. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol. 1988;71:612–4.Google Scholar
  47. 47.
    Cowles TA, Magrina JF, Masterson BJ, Capen CV. Comparison of clinical and surgical staging in patients with endometrial carcinoma. Obstet Gynecol. 1985;66:413–6.Google Scholar
  48. 48.
    Piver MS, Lele SB, Barlow JJ, Blumenson L. Paraaortic lymph node evaluation in stage I endometrial cancer. Obstet Gynecol. 1982;59:97–100.Google Scholar
  49. 49.
    Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995;86:38–42.Google Scholar
  50. 50.
    Obermair A, Geramou M, Gucer F, Denison U, Graf AH, Kapshammer E, et al. Endometrial cancer: accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. Int J Gynecol Cancer. 1999;9:383–6.Google Scholar
  51. 51.
    Mittal KR, Schwartz PE, Barwick KW. Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high-risk and low-risk groups. Cancer. 1988;61:538–45.PubMedGoogle Scholar
  52. 52.
    Nielsen AL, Thomsen HK, Nyholm HCJ. Evaluation of the reproducibility of the revised 1988 International Federation of Gynecology and Obstetrics grading system of endometrial cancers with special emphasis on nuclear grading. Cancer. 1991;68:2303–9.PubMedGoogle Scholar
  53. 53.
    Zaino RJ, Silverberg SG, Norris HJ, Bundy BN, Morrow CP, Okagaki T. The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol. 1994;13:29–36.PubMedGoogle Scholar
  54. 54.
    Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol. 2000;24:1201–8.PubMedGoogle Scholar
  55. 55.
    Taylor RR, Zeller J, Lieberman RW, O’Connor DM. An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol. 1999;74:3–6.PubMedGoogle Scholar
  56. 56.
    Scholten AN, Smit VTHBM, Beerman H, van Putten WLJ, Creutzberg CL. Prognostic significance and interobserver variablility of histologic grading systems form endometrial carcinoma. Cancer. 2004;100:764–72.PubMedGoogle Scholar
  57. 57.
    Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108.PubMedGoogle Scholar
  58. 58.
    Clement PB, Scully RE. Endometrial hyperplasia and carcinoma. In: Clement PB, Young RH, editors. Tumors and tumorlike lesions of the uterine corpus and cervix. New York: Churchill Livingstone; 1993. p. 181–264.Google Scholar
  59. 59.
    Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease, Atlas of tumor pathology, 3rd series, Fascicle 3. Washington, DC: Armed Forces Institute of Pathology; 1992.Google Scholar
  60. 60.
    Hendrickson MR, Kempson RL. Ciliated carcinoma–a variant of endometrial adenocarcinoma. A report of 10 cases. Int J Gynecol Pathol. 1983;2:1–12.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Gould PR, Li L, Henderson DW, Barter RA, Papadimitriou JM. Cilia and ciliogenesis in endometrial adenocarcinomas. Arch Pathol Lab Med. 1986;110:326–30.PubMedGoogle Scholar
  62. 62.
    Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. I. A clinicopathologic study of clear cell carcinoma and secretory carcinoma. Cancer. 1982;49:1511–23.PubMedGoogle Scholar
  63. 63.
    Kurman RJ, Scully RE. Clear cell carcinoma of the endometrium. An analysis of 21 cases. Cancer. 1976;37:872–82.PubMedGoogle Scholar
  64. 64.
    Tobon H, Watkins GJ. Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol. 1985;4:328–35.PubMedGoogle Scholar
  65. 65.
    Dawagne MP, Silverberg SG. Foam cells in endometrial carcinoma. Gynecol Oncol. 1982;13:67–75.PubMedGoogle Scholar
  66. 66.
    Silver SA, Sherman ME. Morphologic and immunophenotypic characterization of foam cells in endometrial lesions. Int J Gynecol Pathol. 1998;17:140–5.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol. 2007;20(11):1156–65.PubMedGoogle Scholar
  68. 68.
    Wei J-J, Paintal A, Keh P. Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases. Arch Pathol Lab Med. 2013;137(11):1574–83.PubMedGoogle Scholar
  69. 69.
    Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008;132(3):402–23.PubMedGoogle Scholar
  70. 70.
    Chekmareva M, Ellenson LH, Pirog EC. Immunohistochemical differences between mucinous and microglandular adenocarcinomas of the endometrium and benign endocervical epithelium. Int J Gynecol Pathol. 2008;27(4):547–54.PubMedGoogle Scholar
  71. 71.
    Alvarez T, Miller E, Duska L, et al. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol. 2012;36:753–61.PubMedGoogle Scholar
  72. 72.
    Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol. 2005;29(2):157–66.PubMedGoogle Scholar
  73. 73.
    Melhem MF, Tobon H. Mucinous adenocarcinoma of the endometrium: a clinico-pathological review of 18 cases. Int J Gynecol Pathol. 1987;6:347–55.PubMedGoogle Scholar
  74. 74.
    Ross JC, Eifel PJ, Cox RS, Kempson RL, Hendrickson MR. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol. 1983;7:715–29.PubMedGoogle Scholar
  75. 75.
    Tiltman AJ. Mucinous carcinoma of the endometrium. Obstet Gynecol. 1980;55:244–7.PubMedGoogle Scholar
  76. 76.
    Czernobilsky B, Katz Z, Lancet M, Gaton E. Endocervical type epithelium in endometrial carcinoma: a report of 10 cases with emphasis on histochemical methods for differential diagnosis. Am J Surg Pathol. 1980;4:481–9.PubMedGoogle Scholar
  77. 77.
    Rawish KR, Desouki MM, Fadare O. Atypical mucinous glandular proliferations in endometrial samplings: follow-up and other clinicopathological findings in 41 cases. Hum Pathol. 2017;63:53–62.PubMedGoogle Scholar
  78. 78.
    Young RH, Scully RE. Uterine carcinomas simulating microglandular hyperplasia. A report of six cases. Am J Surg Pathol. 1992;16:1092–7.PubMedGoogle Scholar
  79. 79.
    Zaloudek C, Hayashi GM, Ryan IP, Powell CB, Miller TR. Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix. Int J Gynecol Pathol. 1997;16:52–9.PubMedGoogle Scholar
  80. 80.
    Malpica A. How to approach the many faces of endometrioid carcinoma. Mod Pathol. 2016;29(Suppl 1):S29–44.PubMedGoogle Scholar
  81. 81.
    Stewart CJR, Crook ML. PAX2 and cyclin D1 expression in the distinction between cervical microglandular hyperplasia and endometrial microglandular-like carcinoma: a comparison with p16, vimentin, and Ki-67. Int J Gynecol Pathol. 2014;34:90–100, 547–554.PubMedGoogle Scholar
  82. 82.
    Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214–8.PubMedGoogle Scholar
  83. 83.
    Mills AM, Longacre TA. Lynch syndrome: female genital tract cancer diagnosis and screening. Surg Pathol Clin. 2016;9(2):201–14.PubMedGoogle Scholar
  84. 84.
    Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993;260:810–2.PubMedGoogle Scholar
  85. 85.
    Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res. 1994;54:5059–63.PubMedGoogle Scholar
  86. 86.
    Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008;26:5965–71.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23:781–9.PubMedGoogle Scholar
  88. 88.
    Ryan P, Mulligan AM, Aronson M, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer. 2012;118:681–8.PubMedGoogle Scholar
  89. 89.
    Mills AM, Liou S, Ford JM, et al. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014;38:1501–9.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, Blokx WA, Dubois SV, van der Linden H, Meijer JW, Mlynek-Kersjes ML, Hoogerbrugge N, Hebeda KM, van Krieken JH. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol. 2008;32(8):1246–51.PubMedGoogle Scholar
  91. 91.
    Mills A, Sloan E, Thomas M, et al. Clinicopathologic comparison of Lynch syndrome-associated and Lynch-like endometrial carcinomas identified on universal screening. Am J Surg Pathol. 2015;40:155–65.Google Scholar
  92. 92.
    Resnick K, Straughn JM, Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol. 2009;114:530–6.PubMedGoogle Scholar
  93. 93.
    Nelen MR, GW PA, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22–23. Nat Genet. 1996;13:114–6.PubMedGoogle Scholar
  94. 94.
    Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50:255–63.PubMedGoogle Scholar
  95. 95.
    Garg K, Karnezis AN, Rabban JT. Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation. Pathology. 2018;50(2):238–56.PubMedGoogle Scholar
  96. 96.
    Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Cancer Netw. 2017;15(1):9–20.Google Scholar
  97. 97.
    Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow RE, Diaz-Montes TP, Palermo R, Kurman RJ. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol. 2014;132(1):33–7.PubMedGoogle Scholar
  98. 98.
    Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31(7):988–98.PubMedGoogle Scholar
  99. 99.
    Mentrikoski MJ, Shah AA, Hanley KZ, Atkins KA. Assessing endometrial hyperplasia and carcinoma treated with progestin therapy. Am J Clin Pathol. 2012;139:524–34.Google Scholar
  100. 100.
    Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642–6.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol. 1990;39:266–71.PubMedGoogle Scholar
  102. 102.
    Dunton CJ, Balsara G, McFarland M, Hernandez E. Uterine papillary serous carcinoma. A review. Obstet Gynecol Surv. 1991;46:97–102.PubMedGoogle Scholar
  103. 103.
    Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma—a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16:600–10.PubMedGoogle Scholar
  104. 104.
    Lee KR, Belinson JL. Papillary serous adenocarcinoma of the endometrium: a clinicopathologic study of 19 cases. Gynecol Oncol. 1992;46:51–4.PubMedGoogle Scholar
  105. 105.
    Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma—a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47:298–305.PubMedGoogle Scholar
  106. 106.
    Demopoulos RI, Genega E, Vamvakas E, Carlson E, Mittal K. Papillary carcinoma of the endometrium: morphometric predictors of survival. Int J Gynecol Pathol. 1996;15:110–8.PubMedGoogle Scholar
  107. 107.
    Sutton GP, Brill L, Michael H, et al. Malignant papillary lesions of the endometrium. Gynecol Oncol. 1987;27:294–304.PubMedGoogle Scholar
  108. 108.
    Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol. 1985;4:279–88.PubMedGoogle Scholar
  109. 109.
    Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814–24.PubMedGoogle Scholar
  110. 110.
    Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268–74.PubMedGoogle Scholar
  111. 111.
    Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177–85.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Kovalev S, Marchenko ND, Gugliotta BG, Chalas E, Chumas J, Moll UM. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol. 1998;29(6):613–9.PubMedGoogle Scholar
  113. 113.
    Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol. 2018; https//
  114. 114.
    Fadare O, Roma AA, Parkash V, Zheng W, Walavalkar V. Does a p53 “wild-type” Immunophenotype exclude a diagnosis of endometrial serous carcinoma? Adv Anat Pathol. 2018;25(1):61–70.PubMedGoogle Scholar
  115. 115.
    Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551–8.PubMedGoogle Scholar
  116. 116.
    Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol. 1990;94(3):247–54.PubMedGoogle Scholar
  117. 117.
    Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2000;13:379–88.PubMedGoogle Scholar
  118. 118.
    Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44(2):109–15.PubMedGoogle Scholar
  119. 119.
    Hedley C, Sriraksa R, Showeil R, Van Noorden S, El-Bahrawy M. The frequency and significance of WT-1 expression in serous endometrial carcinoma. Hum Pathol. 2014;45(9):1879–84.PubMedGoogle Scholar
  120. 120.
    Chambers JT, Merino M, Kohorn EI, et al. Uterine papillary serous carcinoma. Obstet Gynecol. 1987;69:109.PubMedGoogle Scholar
  121. 121.
    Jeffrey JF, Krepart GV, Lotocki RJ. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol. 1986;67:670.PubMedGoogle Scholar
  122. 122.
    Woolas RP, Williams K, McCartney AJ. Uterine papillary serous carcinoma in a 32-year-old with Turner’s syndrome. Gynecol Oncol. 1994;52:395–401.PubMedGoogle Scholar
  123. 123.
    Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74:385–94.PubMedGoogle Scholar
  124. 124.
    Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol. 1998;91:349–54.PubMedGoogle Scholar
  125. 125.
    Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol. 1990;3:120–8.PubMedGoogle Scholar
  126. 126.
    McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol. 2003;34:939–43.PubMedGoogle Scholar
  127. 127.
    Aquino-Parsons C, Lim P, Wong F, Milden-berger M. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol. 1998;71:83–6.PubMedGoogle Scholar
  128. 128.
    Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797–806.PubMedGoogle Scholar
  129. 129.
    Lee KR, Belinson JL. Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma. Am J Surg Pathol. 1991;15:965–73.PubMedGoogle Scholar
  130. 130.
    Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol. 1997;21:1507–14.PubMedGoogle Scholar
  131. 131.
    Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol. 2001;20(3):214–9.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Gehrig PA, Groben PA, Fowler WC Jr, Walton LA, Van Le L. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol. 2001;97:153–7.PubMedGoogle Scholar
  133. 133.
    Soslow RA, Pirog E, Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol. 2000;24:726–32.PubMedGoogle Scholar
  134. 134.
    Chan JK, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev SA, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 2003;90:181–5.PubMedGoogle Scholar
  135. 135.
    Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463–9.PubMedGoogle Scholar
  136. 136.
    Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40:207–17.PubMedGoogle Scholar
  137. 137.
    Webb GA, Lagios MD. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol. 1987;156:1486–91.PubMedGoogle Scholar
  138. 138.
    Kanbour-Shakir A, Tobon H. Primary clear cell carcinoma of the endometrium. A clinicopathologic study of 20 cases. Int J Gynecol Pathol. 1991;10:67–78.PubMedGoogle Scholar
  139. 139.
    Sakuragi N, Hareyama H, Todo Y, Yamada H, Yamamoto R, Fujino T, et al. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta Obstet Gynecol Scand. 2000;79:311–6.PubMedGoogle Scholar
  140. 140.
    Abeler VM, Vergote IB, Kjorstad KE, Trope CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78:1740–7.PubMedGoogle Scholar
  141. 141.
    Hariri N, Qarmali M, Fadare O. Endometrial serous carcinoma with clear-cell change: frequency and immunohistochemical analysis. Int J Surg Pathol. 2018;26(2):126–34.PubMedGoogle Scholar
  142. 142.
    Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol. 2011;18(6):415–37.PubMedGoogle Scholar
  143. 143.
    Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW 3rd, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol. 2013;26(8):1101–10.PubMedGoogle Scholar
  144. 144.
    Han G, Soslow RA, Wethington S, Levine DA, Bogomolniy F, Clement PB, Köbel M, Gilks B, DeLair D. Endometrial carcinomas with clear cells: a study of a heterogeneous group of tumors including interobserver variability, mutation analysis, and immunohistochemistry with HNF-1β. Int J Gynecol Pathol. 2015;34(4):323–33.PubMedGoogle Scholar
  145. 145.
    Iwamoto M, Nakatani Y, Fugo K, Kishimoto T, Kiyokawa T. Napsin a is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol. 2015;46(7):957–62.PubMedGoogle Scholar
  146. 146.
    Fadare O, Desouki MM, Gwin K, Hanley KZ, Jarboe EA, Liang SX, Quick CM, Zheng W, Parkash V, Hecht JL. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38(2):189–96.PubMedGoogle Scholar
  147. 147.
    Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol. 2007;38(7):1074–80.PubMedGoogle Scholar
  148. 148.
    Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 2014;64(4):585–96.PubMedGoogle Scholar
  149. 149.
    Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20(6):580–7.PubMedGoogle Scholar
  150. 150.
    Fadare O, Zhao C, Khabele D, Parkash V, Quick CM, Gwin K, Desouki MM. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours. Pathology. 2015;47(2):105–11.PubMedGoogle Scholar
  151. 151.
    Simon A, Kopolovic J, Beyth Y. Primary squamous cell carcinoma of the endometrium. Gynecol Oncol. 1988;31:454–61.PubMedGoogle Scholar
  152. 152.
    Melin JR, Wanner L, Schulz DM, Cassell EE. Primary squamous cell carcinoma of the endometrium. Obstet Gynecol. 1979;53:115–9.PubMedGoogle Scholar
  153. 153.
    Goodman A, Zukerberg LR, Rice LW, Fuller AF, Young RH, Scully RE. Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol. 1996;61:54–60.PubMedGoogle Scholar
  154. 154.
    Houissa-Vuong S, Catanzano-Laroudie M, Baviera E, Balaton A, Galet B, Gedeon I, et al. Primary squamous cell carcinoma of the endometrium: case history, pathologic findings, and discussion. Diagn Cytopathol. 2002;27:291–3.PubMedGoogle Scholar
  155. 155.
    Ryder DE. Verrucous carcinoma of the endometrium—a unique neoplasm with long survival. Obstet Gynecol. 1982;59:78S–80S.PubMedGoogle Scholar
  156. 156.
    Spiegel GW, Austin RM, Gelven PL. Transitional cell carcinoma of the endometrium. Gynecol Oncol. 1996;60:325–30.PubMedGoogle Scholar
  157. 157.
    Lininger RA, Ashfaq R, Albores-Saavedra J, Tavassoli FA. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation. Cancer. 1997;79:1933–43.PubMedGoogle Scholar
  158. 158.
    Gungor T, Altinkaya SO, Ozat M, Akbay S, Mollamahmutoglu L. Unusual form of superficial spreading squamous cell carcinoma of cervix involving the endometrium, bilateral tubes and ovaries: a case report with literature review. Arch Gynecol Obstet. 2011;283(2):323–7.PubMedGoogle Scholar
  159. 159.
    Fluhmann CF. Squamous epithelium in the endometrium in benign and malignant conditions. Surg Gynecol Obstet. 1928;46:309–16.Google Scholar
  160. 160.
    Abeler VM, Kjorstad KE, Nesland JM. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer. 1991;68:98–105.PubMedGoogle Scholar
  161. 161.
    Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29(10):1316–21.PubMedGoogle Scholar
  162. 162.
    Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology. 2007;39(1):134–8.PubMedGoogle Scholar
  163. 163.
    Huntsman DG, Clement PB, Gilks CB, Scully RE. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol. 1994;18:364–75.PubMedGoogle Scholar
  164. 164.
    Garg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33(6):925–33.PubMedGoogle Scholar
  165. 165.
    Olson N, Twiggs L, Sibley R. Small-cell carcinoma of the endometrium: light microscopic and ultrastructural study of a case. Cancer. 1982;50:760–5.PubMedGoogle Scholar
  166. 166.
    Paz RA, Frigerio B, Sundblad AS, Eusebi V. Small-cell (oat cell) carcinoma of the endometrium. Arch Pathol Lab Med. 1985;109:270–2.PubMedGoogle Scholar
  167. 167.
    Manivel C, Wick MR, Sibley TK. Neuroendocrine differentiation in mullerian neoplasms. An immunohistochemical study of a “pure” endometrial small-cell carcinoma and a mixed mullerian tumor containing small-cell carcinoma. Am J Clin Pathol. 1986;86:438–43.PubMedGoogle Scholar
  168. 168.
    Meydanli MM, Erguvan R, Altinok MT, Ataoglu O, Kafkasli A. Rare case of neuroendocrine small cell carcinoma of the endometrium with paraneoplastic membranous glomerulonephritis. Tumori. 2003;89:213–7.PubMedGoogle Scholar
  169. 169.
    Espinosa I, De Leo A, D’Angelo E, Rosa-Rosa JM, Corominas M, Gonzalez A, Palacios J, Prat J. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Hum Pathol. 2018;72:100–6.PubMedGoogle Scholar
  170. 170.
    Romero-Pérez L, López-García MÁ, Díaz-Martín J, Biscuola M, Castilla MÁ, Tafe LJ, Garg K, Oliva E, Matias-Guiu X, Soslow RA, Palacios J. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol. 2013;26(11):1514–24.PubMedGoogle Scholar
  171. 171.
    Pesce C, Merino MJ, Chambers JT, Nogales F. Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer. Cancer. 1991;68:1799–802.Google Scholar
  172. 172.
    Rawish KR, Buza N, Zheng W, Fadare O. Endometrial carcinoma with trophoblastic components: clinicopathologic analysis of a rare entity. Int J Gynecol Pathol. 2018;37(2):174–90.PubMedGoogle Scholar
  173. 173.
    Deligdisch L, Kase NG, Bleiweiss IJ. Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology. 2000;46:17–21.PubMedGoogle Scholar
  174. 174.
    Kalir T, Seijo L, Deligdisch L, Cohen C. Endometrial adenocarcinoma with chorio-carcinomatous differentiation in an elderly virginal woman. Int J Gynecol Pathol. 1995;14:266–9.PubMedGoogle Scholar
  175. 175.
    Savage J, Subby W, Okagaki T. Adenocarcinoma of the endometrium with trophoblastic differentiation and metastases as choriocarcinoma: a case report. Gynecol Oncol. 1987;26:257–62.PubMedGoogle Scholar
  176. 176.
    Tunc M, Simsek T, Trak B, Uner M. Endometrium adenocarcinoma with chorio-carcinomatous differentiation: a case report. Eur J Gynaecol Oncol. 1998;19:489–91.PubMedGoogle Scholar
  177. 177.
    Black K, Sykes P, Ostor AG. Trophoblastic differentiation in an endometrial carcinoma. Aust N Z J Obstet Gynaecol. 1998;38:472–3.PubMedGoogle Scholar
  178. 178.
    Arends J, Willebrand D, Gans HJD, Swaen GJV, Bosman FT. Adenocarcinoma of the endometrium with glassy cell features—immunohistochemical observations. Histopathology. 1984;8:873–9.PubMedGoogle Scholar
  179. 179.
    Christopherson WM, Alberhasky RC, Connelly PJ. Glassy cell carcinoma of the endometrium. Hum Pathol. 1982;13:418–21.PubMedGoogle Scholar
  180. 180.
    Pitman MB, Young RH, Clement PB, Dickersin GR, Scully RE. Endometrioid carcinoma of the ovary and endometrium, oxyphilic cell type: a report of nine cases. Int J Gynecol Pathol. 1994;13:290–301.PubMedGoogle Scholar
  181. 181.
    Mooney EE, Robboy SJ, Hammond CB, Berchuck A, Bentley RC. Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis. Int J Gynecol Pathol. 1997;16:169–72.PubMedGoogle Scholar
  182. 182.
    Vargas MP, Merino MJ. Lymphoepithelioma-like carcinoma: an unusual variant of endometrial cancer. A report of two cases. Int J Gynecol Pathol. 1998;17:272–6.PubMedGoogle Scholar
  183. 183.
    Jones MA, Young RH, Scully RE. Endometrial adenocarcinoma with a component of giant cell carcinoma. Int J Gynecol Pathol. 1991;10:260–70.PubMedGoogle Scholar
  184. 184.
    Joseph MG, Fellows FG, Hearn SA. Primary endodermal sinus tumor of the endometrium. A clinicopathologic, immuno-cytochemical, and ultrastructural study. Cancer. 1990;63:297–302.Google Scholar
  185. 185.
    Ohta M, Sakakibara K, Mizuno K, Kano T, Matsuzawa K, Tomoda Y, et al. Successful treatment of primary endodermal sinus tumor of the endometrium. Gynecol Oncol. 1988;31:357–64.Google Scholar
  186. 186.
    Hoshida Y, Nagakawa T, Mano S, Taguchi K, Aozasa K. Hepatoid adenocarcinoma of the endometrium associated with alpha–fetoprotein production. Int J Gynecol Pathol. 1996;15:266–9.PubMedGoogle Scholar
  187. 187.
    Daya D, Lukka H, Clement PB. Primitive neuroectodermal tumors of the uterus—a report of four cases. Hum Pathol. 1992;23:1120–9.PubMedGoogle Scholar
  188. 188.
    Hendrickson MR, Scheithauer BW. Primitive neuroectodermal tumor of the endometrium: report of two cases, one with electron microscopic observations. Int J Gynecol Pathol. 1986;5:249–59.PubMedGoogle Scholar
  189. 189.
    Sinkre P, Albores-Saavedra J, Miller DS, Copeland LJ, Hameed A. Endometrial endometrioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor. Int J Gynecol Pathol. 2000;19:127–32.PubMedGoogle Scholar
  190. 190.
    Sorensen JB, Schultze HR, Madsen EL, Holund B. Primitive neuroectodermal tumor (PNET) of the uterine cavity. Eur J Obstet Gynecol Reprod Biol. 1998;76:181–4.PubMedGoogle Scholar
  191. 191.
    Fraggetta F, Magro G, Vasquez E. Primitive neuroectodermal tumour of the uterus with focal cartilaginous differentiation. Histopathology. 1997;30:483–5.PubMedGoogle Scholar
  192. 192.
    Bittencourt AL, Britto JF, Fonseca LEJ. Wilms’ tumor of the uterus: the first report of the literature. Cancer. 1981;47:2496–9.PubMedGoogle Scholar
  193. 193.
    Muc RS, Grayson W, Grobbelaar JJ. Adult extrarenal Wilms tumor occurring in the uterus. Arch Pathol Lab Med. 2001;125:1081–3.PubMedGoogle Scholar
  194. 194.
    Damato S, Haldar K, McCluggage WG. Primary endometrial yolk sac tumor with endodermal-intestinal differentiation masquerading as metastatic colorectal adenocarcinoma. Int J Gynecol Pathol. 2016;35(4):316–20.PubMedGoogle Scholar
  195. 195.
    Zaloudek CJ, Hendrickson MR, Soslow RA. Mesenchymal tumors of the uterus. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein’s pathology of the female genital tract. 6th ed. New York: Springer; 2011. p. 453–527.Google Scholar
  196. 196.
    Clement PB, Scully RE. Tumors with mixed epithelial and mesenchymal elements. In: Clement PB, Young RH, editors. Tumors and tumorlike lesions of the uterine corpus and cervix. New York: Churchill Livingstone; 1993. p. 329–70.Google Scholar
  197. 197.
    Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol. 1995;19(6):666–74.PubMedGoogle Scholar
  198. 198.
    Geisinger KR, Dabbs DJ, Marshall RB. Malignant mixed mullerian tumors. An ultrastructural and immunohistochemical analysis with histogenetic considerations. Cancer. 1987;59:1781–90.PubMedGoogle Scholar
  199. 199.
    Cerilli LA, Wick MR. Immunohistology of soft tissue and osseous neoplasms. In: Dabbs DJ, editor. Diagnostic immunohistochemistry. Philadelphia: Churchill Livingstone; 2002. p. 59–112.Google Scholar
  200. 200.
    Clement PB. Tumorlike lesions of the uterine corpus. In: Clement PB, Young RH, editors. Tumors and tumorlike lesions of the uterine corpus and cervix. New York: Churchill Livingstone; 1993. p. 137–79.Google Scholar
  201. 201.
    Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997;57:5379–85.PubMedGoogle Scholar
  202. 202.
    Segev Y, Arnon E, Siegler E, Gemer O, Goldberg Y, Auslender R, Kaldawy A, Lavie O. High incidence of carcinosarcoma among patients previously treated with tamoxifen. Isr Med Assoc J. 2017;19(3):164–7.PubMedGoogle Scholar
  203. 203.
    McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton S, Beattie J, Al-Nafussi A. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer. 2000;10(4):280–4.PubMedGoogle Scholar
  204. 204.
    Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, Cailleux PE, Lhomme C. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer. 2002;12(5):496–500.PubMedGoogle Scholar
  205. 205.
    Seidman JD, Kumar D, Cosin JA, et al. Carcinomas of the female genital tract occurring after pelvic irradiation: a report of 15 cases. Int J Gynecol Pathol. 2006;25:293–7.PubMedGoogle Scholar
  206. 206.
    Meis JM, Lawrence WD. The immunohistochemical profile of malignant mixed mullerian tumor. Overlap with endometrial adenocarcinoma. Am J Clin Pathol. 1990;94:1–7.PubMedGoogle Scholar
  207. 207.
    Colombi RP. Sarcomatoid carcinomas of the female genital tract (malignant mixed mullerian tumors). Semin Diagn Pathol. 1993;10:169–75.PubMedGoogle Scholar
  208. 208.
    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.PubMedGoogle Scholar
  209. 209.
    Richmond AM, Blake EA, Torkko K, Smith EE, Spillman MA, Post MD. Fascin is associated with aggressive behavior and poor outcome in uterine carcinosarcoma. Int J Gynecol Cancer. 2017;27(9):1895–903.PubMedGoogle Scholar
  210. 210.
    Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, Van De Vijver K, Biscuola M, López-García MÁ, Prat J, Matías-Guiu X, Cano A, Oliva E, Palacios J. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 2011;223(1):72–80.PubMedGoogle Scholar
  211. 211.
    Stewart CJ, McCluggage WG. Epithelial-mesenchymal transition in carcinomas of the female genital tract. Histopathology. 2013;62:31–43.PubMedGoogle Scholar
  212. 212.
    Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus. A clinicopathologic study of 35 cases. Cancer. 1981;48:354–66.PubMedGoogle Scholar
  213. 213.
    Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a gynecologic oncology group clinicopathologic study of 31 cases. Int J Gynecol Pathol. 1992;11:75–88.PubMedGoogle Scholar
  214. 214.
    Abell MR. Papillary adenofibroma of the uterine cervix. Am J Obstet Gynecol. 1971;110:990–3.PubMedGoogle Scholar
  215. 215.
    Kerner H, Lichtig C. Mullerian adenosarcoma presenting as cervical polyps—a report of seven cases and review of the literature. Obstet Gynecol. 1993;81:655–9.PubMedGoogle Scholar
  216. 216.
    Clement PB. Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol. 1989;13:28–38.PubMedGoogle Scholar
  217. 217.
    Clement PB, Scully RE. Mullerian adenosarcomas of the uterus with sex cord–like elements. Am J Clin Pathol. 1989;91:664–72.PubMedGoogle Scholar
  218. 218.
    Tavassoli FA, Norris HJ. Mesenchymal tumors of the uterus. VII. A clinicopathologic study of 60 endometrial stromal nodules. Histopathology. 1981;5:1–10.PubMedGoogle Scholar
  219. 219.
    Chen X, Arend R, Hamele-Bena D, Tergas AI, Hawver M, Tong GX, Wright TC, Wright JD. Uterine carcinosarcomas: clinical, histopathologic and Immunohistochemical characteristics. Int J Gynecol Pathol. 2017;36(5):412–9.PubMedGoogle Scholar
  220. 220.
    Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol. 1998;69:253–7.PubMedGoogle Scholar
  221. 221.
    Auerbach HE, Livolsi VA, Merino MJ. Malignant mixed mullerian tumors of the uterus. An immunohistochemical study. Int J Gynecol Pathol. 1988;7:123–30.PubMedGoogle Scholar
  222. 222.
    Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson EM, Yandell RB. Mixed mullerian tumors of the uterus. A clinicopathologic study. Obstet Gynecol. 1989;74:388–92.PubMedPubMedCentralGoogle Scholar
  223. 223.
    Gagne H, Tetu B, Blondeau L, Raymond PE, Blais R. Morphologic prognostic factors of malignant mixed mullerian tumor of the uterus: a clinicopathologic study of 58 cases. Mod Pathol. 1989;2:433–8.PubMedGoogle Scholar
  224. 224.
    Young RH, Kleinman GM, Scully RE. Glioma of the uterus. Report of a case with comments on histogenesis. Am J Surg Pathol. 1981;5:695–9.PubMedGoogle Scholar
  225. 225.
    Gersell DJ, Duncan DA, Fulling KH. Malignant mixed mullerian tumor of the uterus with neuroectodermal differentiation. Int J Gynecol Pathol. 1989;8:169–78.PubMedGoogle Scholar
  226. 226.
    Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S 55–60.Google Scholar
  227. 227.
    Ferguson SE, Tornos C, Hummer A, et al. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007;31:1653–61.PubMedGoogle Scholar
  228. 228.
    Azumi N, Czernobilsky B. Immunohistochemistry. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 5th ed. New York: Springer; 2002. p. 1251–76.Google Scholar
  229. 229.
    Hart WR, Yoonessi M. Endometrial stromatosis of the uterus. Obstet Gynecol. 1977;49:393–403.PubMedGoogle Scholar
  230. 230.
    McCluggage WG. Pathologic staging of endometrial carcinomas: selected areas of difficulty. Adv Anat Pathol. 2018;25(2):71–84.PubMedGoogle Scholar
  231. 231.
    Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002;41:185–207.PubMedGoogle Scholar
  232. 232.
    Busca A, Mirkovic J, Parra-Herran C. Gastric-type endocervical adenocarcinoma involving the endometrium and clinically mimicking endometrial neoplasia: a diagnostic challenge. Am J Surg Pathol. 2018;42:983.PubMedGoogle Scholar
  233. 233.
    Fujiwara M, Longacre TA. Low-grade mucinous adenocarcinoma of the uterine corpus: a rare and deceptively bland form of endometrial carcinoma. Am J Surg Pathol. 2011;35:537–44.PubMedGoogle Scholar
  234. 234.
    Kurakagi C, Enomoto T, Ueno Y, et al. Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Investig. 83:35–45.Google Scholar
  235. 235.
    Iaconis L, Hyjek E, Ellenson LH, Pirog EC. p16 and Ki-67 immunostaining in atypical immature squamous metaplasia of the uterine cervix: correlation with human papillomavirus detection. Arch Pathol Lab Med. 2007;131:1343–9.PubMedGoogle Scholar
  236. 236.
    Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/ CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A. 1996;93:4350–4.PubMedPubMedCentralGoogle Scholar
  237. 237.
    Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997;237:7–13.PubMedGoogle Scholar
  238. 238.
    Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127:265–75.PubMedGoogle Scholar
  239. 239.
    Murphy N, Heffron CC, King B, et al. p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch. 2004;445:610–5.PubMedGoogle Scholar
  240. 240.
    Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186–92.PubMedGoogle Scholar
  241. 241.
    Parwani AV, Smith Sehdev AE, Kurman RJ, Ronnett BM. Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: clinicopathologic features, human papillomavirus DNA detection, and P16 expression. Hum Pathol. 2005;36:82–90.PubMedGoogle Scholar
  242. 242.
    Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741–8.PubMedPubMedCentralGoogle Scholar
  243. 243.
    Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol. 2001;8:83–92.PubMedGoogle Scholar
  244. 244.
    Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525–41.Google Scholar
  245. 245.
    Durst M, Glitz D, Schneider A, zur Hausen H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology. 1992;189:132–40.PubMedGoogle Scholar
  246. 246.
    Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol. 1992;23:117–28.PubMedGoogle Scholar
  247. 247.
    McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol. 2003;22:231–5.PubMedGoogle Scholar
  248. 248.
    Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004;28:160–7.PubMedGoogle Scholar
  249. 249.
    Yemelyanova A, Ji H, Shih Ie M, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504–14.PubMedGoogle Scholar
  250. 250.
    Kong CS, Beck AH, Longacre TA. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2010;34:915–26.PubMedPubMedCentralGoogle Scholar
  251. 251.
    Staebler A, Sherman ME, Zaino RJ, Ronnett BM. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol. 2002;26(8):998–1006.PubMedGoogle Scholar
  252. 252.
    Kamoi S, AlJuboury MI, Akin MR, Silverberg SG. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol. 2002;21:217–23.PubMedGoogle Scholar
  253. 253.
    McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002;21:11–5.PubMedGoogle Scholar
  254. 254.
    Zhang X, Lin Z, Lee ES, Kim I. Immunohistochemical profiles of endometrial and endocervical adenocarcinomas. Mod Pathol. 2003;16:217A.Google Scholar
  255. 255.
    Ansari-Lari MA, Staebler A, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: p16 expression correlated with human papillomavirus (HPV) DNA detection by in situ hybridization (ISH). Mod Pathol. 2003;16:180A.Google Scholar
  256. 256.
    Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002;21:4–10.PubMedGoogle Scholar
  257. 257.
    Kumar A, Schneider V. Metastases to the uterus from extrapelvic primary tumors. Int J Gynecol Pathol. 1983;2:134–40.PubMedGoogle Scholar
  258. 258.
    Kumar NB, Hart WR. Metastases to the uterine corpus from extagenital cances. A clinicopathologic study of 63 cases. Cancer. 1982;50:2163–9.PubMedGoogle Scholar
  259. 259.
    Mazur MT, Hsueh S, Gersell DJ. Metastases to the female genital tract. Analysis of 325 cases. Cancer. 1984;53:1978–84.PubMedPubMedCentralGoogle Scholar
  260. 260.
    Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol. 1985;16:28–34.PubMedGoogle Scholar
  261. 261.
    Eifel P, Hendrickson M, Ross J, Ballon S, Martinez A, Kempson RL. Simultaneous presentation of carcinoma involving the ovary and uterine corpus. Cancer. 1982;50:163–70.PubMedGoogle Scholar
  262. 262.
    Schultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, Perez Mies B, Soslow RA, Lim RS, Viale A, Huberman KH, Palacios JC, Reis-Filho JS, Matias-Guiu X, Weigelt B. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst. 2016;108(6):djv427.PubMedPubMedCentralGoogle Scholar
  263. 263.
    Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, Mackenzie R, Grewal DS, Li-Chang H, Karnezis AN, Sheffield BS, McConechy MK, Kommoss F, Taran FA, Staebler A, Shah SP, Wallwiener D, Brucker S, Gilks CB, Kommoss S, Huntsman DG. Synchronous endometrial and ovarian carcinomas: evidence of Clonality. J Natl Cancer Inst. 2016;108(6):djv428.PubMedGoogle Scholar
  264. 264.
    Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am J Surg Pathol. 1986;10:568–76.PubMedGoogle Scholar
  265. 265.
    Gown AM. Immunohistochemical determination of primary sites of carcinomas. J Histotechnol. 1999;22:209–15.Google Scholar
  266. 266.
    Ni YB, Tsang JYS, Shao MM, Chan SK, Cheung SY, Tong J, To KF, Tse GM. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Breast Cancer Res Treat. 2018;169(1):25–32.PubMedGoogle Scholar
  267. 267.
    Winkler B, Alvarez S, Richart RM, Crum CP. Pitfalls in the diagnosis of endometrial neoplasia. Obstet Gynecol. 1984;64:185–94.PubMedGoogle Scholar
  268. 268.
    Crum CP, Richart RM, Fenoglio CM. Adenoacanthosis of the endometrium. A clinicopathologic study in premenopausal women. Am J Surg Pathol. 1981;5:15.PubMedGoogle Scholar
  269. 269.
    Hendrickson MR, Kempson RL. Endometrial epithelial metaplasias: proliferations frequently misdiagnosed as adenocarcinoma. Report of 89 cases and proposed classification. Am J Surg Pathol. 1980;4:525–42.PubMedGoogle Scholar
  270. 270.
    Blaustein A. Morular metaplasia misdiagnosed as adenoacanthoma in young women with polycystic ovarian disease. Am J Surg Pathol. 1982;6:223.PubMedGoogle Scholar
  271. 271.
    Andersen WA, Taylor PT, Fechner RE, Pinkerton JAV. Endometrial metaplasia associated with endometrial carcinoma. Am J Obstet Gynecol. 1987;157:597–604.PubMedGoogle Scholar
  272. 272.
    Clement PB. Pathology of the uterine corpus. Hum Pathol. 1991;22:776–91.Google Scholar
  273. 273.
    Zaman SS, Mazur MT. Endometrial papillary syncytial change. A nonspecific alteration associated with active breakdown. Am J Clin Pathol. 1993;99:741–5.PubMedPubMedCentralGoogle Scholar
  274. 274.
    Kaku T, Tsukamoto N, Tsuruchi N, Sugihara K, Kamura T, Nakano H. Endometrial metaplasia associated with endometrial carcinoma. Obstet Gynecol. 1992;80:812–6.PubMedGoogle Scholar
  275. 275.
    Rorat E, Wallach RC. Papillary metaplasia of the endometrium: clinical and histopathologic considerations. Obstet Gynecol. 1984;64:90S–2S.PubMedGoogle Scholar
  276. 276.
    Sherman ME, Mazur MT, Kurman RJ. Benign diseases of the endometrium. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 5th ed. New York: Springer; 2002. p. 421–66.Google Scholar
  277. 277.
    Mazur MT. Atypical polypoid adenomyomas of the endometrium. Am J Surg Pathol. 1981;5:473–82.PubMedGoogle Scholar
  278. 278.
    Young RH, Treger T, Scully RE. Atypical polypoid adenomyoma of the uterus. A report of 27 cases. Am J Clin Pathol. 1986;86:139–45.PubMedGoogle Scholar
  279. 279.
    Iezzoni JC, Mills SE. Nonneoplastic endometrial signet-ring cells. Vacuolated decidual cells and stromal histiocytes mimicking adenocarcinoma. Am J Clin Pathol. 2001;115:249–55.PubMedPubMedCentralGoogle Scholar
  280. 280.
    Fukunaga M, Iwaki S. Nodular histiocytic hyperplasia of the endometrium. Arch Pathol Lab Med. 2004;128(9):1032–4.PubMedGoogle Scholar
  281. 281.
    Chebib I, Chu P, Duggan MA, DiFrancesco LM. Primary signet-ring cell adenocarcinoma of the endometrium: case report and review of the literature. Int J Gynecol Pathol. 2010;29(3):269–72.PubMedGoogle Scholar
  282. 282.
    Boyd C, Cameron I, McCluggage WG. Endometrial adenocarcinoma with signet ring cells: report of two cases of an extremely rare phenomenon. Int J Gynecol Pathol. 2010;29(6):579–82.PubMedGoogle Scholar
  283. 283.
    Pusiol T. HPV11 positive endometrioid carcinoma of the endometrium with signet-ring cells: diagnostic criteria and review of the literature. Case Rep Pathol. 2014;2014:1.Google Scholar
  284. 284.
    Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well–differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434–40.PubMedGoogle Scholar
  285. 285.
    Fadare O, Parkash V, Dupont WD, Acs G, Atkins KA, Irving JA, Pirog EC, Quade BJ, Quddus MR, Rabban JT 3rd, Vang R, Hecht JL. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol. 2012;36(8):1107–18.PubMedGoogle Scholar
  286. 286.
    Silva EG, Young RH. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol. 2007;31(8):1203–8.PubMedGoogle Scholar
  287. 287.
    Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer. 1966;19:755–66.PubMedGoogle Scholar
  288. 288.
    Yoonessi M, Hart WR. Endometrial stromal sarcomas. Cancer. 1977;40:898–906.PubMedGoogle Scholar
  289. 289.
    Mhawech-Fauceglia P, Yan L, Liu S, Pejovic T. ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology. 2013;62(7):976–85.PubMedGoogle Scholar
  290. 290.
    Allo G, Bernardini MQ, Wu RC, Shih IM, Kalloger S, Pollett A, Gilks CB, Clarke BA. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 2014;27(2):255–61.PubMedGoogle Scholar
  291. 291.
    Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA. International endocervical adenocarcinoma criteria and classification (IECC): A new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol. 2018;42(2):214–26.PubMedGoogle Scholar
  292. 292.
    Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors. Int J Gynecol Cancer. 2013;23(2):380–4.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Tricia A. Murdock
    • 1
  • Emanuela F. T. Veras
    • 1
  • Robert J. Kurman
    • 1
  • Michael T. Mazur
    • 2
  1. 1.Department of PathologyThe Johns Hopkins HospitalBaltimoreUSA
  2. 2.Department of Pathology and Laboratory MedicineState University of New York Upstate Medical UniversitySyracuseUSA

Personalised recommendations